Skip To Main Content

Venclexta (venetoclax)

Prescribing Information

Medication Guide

Safety Data Sheets:

VENCLEXTA^® Tablets (10, 50 and 100 mg)

Hands shaking over contract icon

Acute Myeloid Leukemia

Azacitidine and Venetoclax versus Induction Chemotherapy for Untreated Acute Myeloid Leukemia (AML)

PARADIGM is a Phase 2, randomized, open-label, multicenter study evaluating the efficacy and safety of azacitidine plus venetoclax versus induction chemotherapy (IC) in newly diagnosed IC-eligible patients with AML.

The publication has been summarized for educational purposes and is available here:

Fathi AT, Perl AE, Fell GG, et al. Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia. N Engl J Med. 2026;395(9):845-858. doi:10.1056/NEJMoa2602804

Looking for more information?

Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.

Connect with an MSL

Submit a Request

Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT